Inhibitor Therapeutics Net Income

Inhibitor Therapeutics (CBTE) currently reports a net income of $-3.3M as of June 2026. That compares with $-3.4M in the prior-year period — up 4.0% year over year. That is below the Healthcare sector average of $72B. Use the charts on this page to explore Inhibitor Therapeutics's net income history and peer comparisons.

Inhibitor Therapeutics's net income increased from $-3.4M to $-3.3M — a 4.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inhibitor Therapeutics's net income of $-3.3M is lower than the Healthcare sector average of $72B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Inhibitor Therapeutics reported $-3.3M in net income as of June 2026. That compares with $-3.4M in the prior-year period — up 4.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-3.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $72B. From there, open related valuation or income-statement pages for Inhibitor Therapeutics, and consider following CBTE for alerts when major investors trade the stock.